Roles of Toll-like receptors in transplantation

Current Opinion in Organ Transplantation

Volumn 19, Issue 1, 2014, Pages 1-7

  Wu, Huiling ^a   Chadban, Steven J ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

endogenous ligands; innate and adaptive immunity; rejection; tolerance; Toll like receptors

Indexed keywords

EID: 84895909679     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000038     Document Type: Review

References (50)

1. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11:373-384.
2. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-995.
3. Oyama J, Blais C Jr, Liu X, et al. Reduced myocardial ischemia-reperfusion injury in Toll-like receptor 4-deficient mice. Circulation 2004; 109:784-789.
4. Shishido T, Nozaki N, Yamaguchi S, et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003; 108:2905-2910.
5. Zhai Y, Shen XD, O'Connell R, et al. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J Immunol 2004; 173:7115- 7119.
6. Wolfs TG, Buurman WA, van Schadewijk A, et al. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-Alpha mediated up-regulation during inflammation. J Immunol 2002; 168:1286-1293.
7. Wu H, Chen G, Wyburn KR, et al. TLR4 activation mediates kidney ischemia/ reperfusion injury. J Clin Invest 2007; 117:2847-2859.
8. Chen J, John R, Richardson JA, et al. Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury. Kidney Int 2011; 79:288-299.
9. Leemans JC, Stokman G, Claessen N, et al. Renal-Associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005; 115:2894- 2903.
10. Shimamoto A, Pohlman TH, Shomura S, et al. Toll-like receptor 4 mediates lung ischemia-reperfusion injury. Ann Thorac Surg 2006; 82:2017-2023.
11. Hyakkoku K, Hamanaka J, Tsuruma K, et al. Toll-like receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal cerebral ischemia. Neuroscience 2010; 171:258-267.
12. Lehnardt S, Lehmann S, Kaul D, et al. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. J Neuroimmunol 2007; 190:28-33.
13. Yang H, Hreggvidsdottir HS, Palmblad K, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A 2010; 107:11942-11947.
14. Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201:1135-1143.
15. Wu H, Ma J, Wang P, et al. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol 2010; 21:1878-1890.
16. Andrassy M, Volz HC, Igwe JC, et al. High-mobility group box-1 in ischemiareperfusion injury of the heart. Circulation 2008; 117:3216-3226.
17. Zhu H, Li J, Wang S, et al. Hmgb1-TLR4-IL-23-IL-17A axis promote ischemiareperfusion injury in a cardiac transplantation model. Transplantation 2013; 95:1448-1454.
18. Lech M, Avila-Ferrufino A, Allam R, et al. Resident dendritic cells prevent postischemic acute renal failure by help of single Ig IL-1 receptor-related protein. J Immunol 2009; 183:4109-4118.
19. Noris M, Cassis P, Azzollini N, et al. The toll-IL-1R member Tir8/SIGIRR negatively regulates adaptive immunity against kidney grafts. J Immunol 2009; 183:4249-4260.
20. Izuishi K, Tsung A, Jeyabalan G, et al. Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J Immunol 2006; 176:7154-7158.
21. & Wu H, Steenstra R, de Boer CS, et al. Preconditioning with recombinant highmobility group box1 protein protects the kidney against ischemia reperfusion injury in mice. Kidney Int 2013; In press.
22. Kruger B, Krick S, Dhillon N, et al. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci U S A 2009; 106:3390-3395.
23. Dhillon N, Walsh L, Kruger B, et al. A single nucleotide polymorphism of Tolllike receptor 4 identifies the risk of developing graft failure after liver transplantation. J Hepatol 2010; 53:67-72.
24. Goldstein DR, Tesar BM, Akira S, et al. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003; 111:1571-1578.
25. Tesar BM, Zhang J, Li Q, et al. TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a Toll-like receptor signal adaptor protein. Am J Transplant 2004; 4:1429-1439.
26. & Wu H, Noordmans GA, O'Brien MR, et al. Absence of MyD88 signaling induces donor-specific kidney allograft tolerance. J Am Soc Nephrol 2012; 23:1701-1716.
27. & Zhang X, Beduhn M, Zheng X, et al. Induction of alloimmune tolerance in heart transplantation through gene silencing of TLR adaptors. Am J Transplant 2012; 12:2675-2688.
28. Zhang N, Kruger B, Lal G, et al. Inhibition of TLR4 signaling prolongs Tregdependent murine islet allograft survival. Immunol Lett 2010; 127:119-125.
29. Hutton MJ, Westwell-Roper C, Soukhatcheva G, et al. Islet allograft rejection is independent of Toll-like receptor signaling in mice. Transplantation 2009; 88:1075-1080.
30. Palmer SM, Burch LH, Davis RD, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003; 168:628-632.
31. & Cantu E, Lederer DJ, Meyer K, et al. Gene set enrichment analysis identifies key innate immune pathways in primary graft dysfunction after lung transplantation. Am J Transplant 2013; 13:1898-1904.
32. Palmer SM, Burch LH, Mir S, et al. Donor polymorphisms in Toll-like receptor- 4 influence the development of rejection after renal transplantation. Clin Transplant 2006; 20:30-36.
33. Ducloux D, Deschamps M, Yannaraki M, et al. Relevance of Toll-like receptor- 4 polymorphisms in renal transplantation. Kidney Int 2005; 67:2454-2461.
34. Tesar BM, Jiang D, Liang J, et al. The role of hyaluronan degradation products as innate alloimmune agonists. Am J Transplant 2006; 6:2622-2635.
35. Huang Y, Yin H, Han J, et al. Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 2007; 7:799-808.
36. Matsuoka N, Itoh T, Watarai H, et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. J Clin Invest 2010; 120:735-743.
37. Wang S, Schmaderer C, Kiss E, et al. Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88- and TRIF-dependent signaling. Dis Model Mech 2010; 3:92-103.
38. Methe H, Zimmer E,Grimm C, et al. Evidence for a role of Toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation 2004; 78:1324-1331.
39. Braudeau C, Ashton-Chess J, Giral M, et al. Contrasted blood and intragraft Toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients. Transplantation 2008; 86:130-136.
40. & Howell J, Sawhney R, Skinner N, et al. Toll-like receptor 3 and 7/8 function is impaired in hepatitis C rapid fibrosis progression postliver transplantation. Am J Transplant 2013; 13:943-953.
41. Thornley TB, Brehm MA, Markees TG, et al. TLR agonists abrogate costimulation blockade-induced prolongation of skin allografts. J Immunol 2006; 176:1561-1570.
42. Porrett PM, Yuan X, LaRosa DF, et al. Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol 2008; 181:1692-1699.
43. Chen L, Wang T, Zhou P, et al. TLR engagement prevents transplantation tolerance. Am J Transplant 2006; 6:2282-2291.
44. Thornley TB, Phillips NE, Beaudette-Zlatanova BC, et al. Type 1 IFN mediates cross-talk between innate and adaptive immunity that abrogates transplantation tolerance. J Immunol 2007; 179:6620-6629.
45. Walker WE, Nasr IW, Camirand G, et al. Absence of innate MyD88 signaling promotes inducible allograft acceptance. J Immunol 2006; 177:5307-5316.
46. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4CD25T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-1036.
47. Shen H, Goldstein DR. IL-6 and TNF-Alpha synergistically inhibit allograft acceptance. J Am Soc Nephrol 2009; 20:1032-1040.
48. Burrell BE, Csencsits K, Lu G, et al. CD8 Th17 mediate costimulation blockade-resistant allograft rejection in T-bet-deficient mice. J Immunol 2008; 181:3906-3914.
49. Arslan F, Houtgraaf JH, Keogh B, et al. Treatment with OPN-305, a humanized anti-Toll-like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv 2012; 5:279-287.
50. Farrar CA, Keogh B, McCormack W, et al. Inhibition of TLR2 promotes graft function in a murine model of renal transplant ischemia-reperfusion injury. FASEB J 2012; 26:799-807.